Stem cells for ALS: An overview of possible therapeutic approaches

International Journal of Developmental Neuroscience

Volumn 57, Issue , 2017, Pages 46-55

  Czarzasta, Joanna ^a   Habich, Aleksandra ^a   Siwek, Tomasz ^a   Czapliński, Adam ^a,b   Maksymowicz, Wojciech ^a   Wojtkiewicz, Joanna ^a,c  

^a UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^b Neurology   (Switzerland)

^c Foundation for Nerve Cells Regeneration   (Poland)

Author keywords

Amyotrophic lateral sclerosis; Risk factors; Stem cells therapy

Indexed keywords

ALDEHYDE DEHYDROGENASE; COPPER ZINC SUPEROXIDE DISMUTASE; GAMMA INTERFERON; GLUTATHIONE; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; REACTIVE OXYGEN METABOLITE; TAR DNA BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BLOOD SPINAL CORD BARRIER; BONE MARROW MESENCHYMAL STEM CELL TRANSPLANTATION; C9ORF72 GENE; CENTRAL NERVOUS SYSTEM FUNCTION; DIETARY INTAKE; DISEASE COURSE; EMBRYONIC STEM CELL TRANSPLANTATION; ENZYME ACTIVITY; FEASIBILITY STUDY; GENE; GOOD MANUFACTURING PRACTICE; HUMAN; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY ENSHEATHING STEM CELLS TRANSPLANTATION; PARACRINE SIGNALING; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; REVIEW; SMOKING; SOD1 GENE; STEM CELL TRANSPLANTATION; TARDP GENE; UMBILICAL CORD BLOOD CELL TRANSPLANTATION; UPREGULATION; ANIMAL; PHYSIOLOGY; PROCEDURES; STEM CELL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 85009902120     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2017.01.003     Document Type: Review

References (107)

1. Aggarwal, S., Pittenger, M.F., Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005), 1815–1822.
2. Ahmed, A., Wicklund, M.P., Amyotrophic lateral sclerosis: what role does environment play. Neurol. Clin. 29 (2011), 689–711.
3. Al-Chalabi, A., Kwak, S., Mehler, M., et al. Genetic and epigenetic studies of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 14:Suppl 1 (2013), 44–52.
4. Bae, K.S., Park, J.B., Kim, H.S., Kim, D.S., Park, D.J., Kang, S.J., Neuron-like differentiation of bone marrow-derived mesenchymal stem cells. Yonsei Med. J. 52 (2011), 401–412.
5. Barber, S.C., Shaw, P.J., Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 48 (2010), 629–641.
6. Bigini, P., Veglianese, P., Andriolo, G., et al. Intracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration. Rejuvenation Res. 14 (2011), 623–639.
7. Blanquer, M., Moraleda, J.M., Iniesta, F., et al. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. Stem Cells 30 (2012), 1277–1285.
8. Boido, M., Piras, A., Valsecchi, V., Spigolon, G., Mareschi, K., Ferrero, I., Vizzini, A., Temi, S., Mazzini, L., Fagioli, F., Vercelli, A., Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateral sclerosis. Cytotherapy 16 (2014), 1059–1072.
9. Boulis, N.M., Federici, T., Glass, J.D., et al. Translational stem cell therapy for amyotrophic lateral sclerosis. Nat. Rev. Neurol. 8 (2011), 172–176.
10. Bucchia, M., Ramirez, A., Parente, V., et al. Therapeutic development in amyotrophic lateral sclerosis. Clin. Ther. 37 (2015), 668–680.
11. Cashman, N., Tan, L.Y., Krieger, C., et al. Pilot study of granulocyte colony stimulating factor (G-CSG)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve 37 (2008), 620–625.
12. Chiò, A., Mora, G., La Bella, V., et al. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve 43 (2011), 189–195.
13. Conradi, S., Ronnevi, L.O., Vesterberg, O., Lead concentration in skeletal muscle in amyotrophic lateral sclerosis patients and control subjects. J. Neurol. Neurosurg. Psychiatry 41 (1978), 1001–1004.
14. Conradi, S., Ronnevi, L.O., Nise, G., Vesterberg, O., Abnormal distribution of lead in amyotrophic lateral sclerosis-reestimation of lead in the cerebrospinal fluid. J. Neurol. Sci. 48 (1980), 413–418.
15. Cossetti, C., Iraci, N., Mercer, T.R., Leonardi, T., Alpi, E., Drago, D., Alfaro-Cervello, C., Saini, H.K., Davis, M.P., Schaeffer, J., Vega, B., Stefanini, M., Zhao, C., Muller, W., Garcia-Verdugo, J.M., Mathivanan, S., Bachi, A., Enright, A.J., Mattick, J.S., Pluchino, S., Extracellular vesicles from neural stem cells transfer IFN-γ via Ifngr1 to activate Stat1 signaling in target cells. Mol. Cell 56 (2014), 193–204.
16. Deda, H., Inci, M.C., Kürekçi, A.E., et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 11 (2009), 18–25.
17. Deshpande, D.M., Kim, Y.S., Martinez, T., et al. Recovery from paralysis in adult rats using embryonic stem cells. Ann. Neurol. 60 (2006), 32–44.
18. Dimos, J.T., Rodolfa, K.T., Niakan, K.K., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321 (2008), 1218–1221.
19. Ehrhart, J., Smith, A.J., Kuzmin-Nichols, N., Zesiewicz, T.A., Jahan, I., Shytle, R.D., Kim, S.H., Sanberg, C.D., Vu, T.H., Gooch, C.L., Sanberg, P.R., Garbuzova-Davis, S., Humoral factors in ALS patients during disease progression. J. Neuroinflammation, 28(12), 2015, 127.
20. Endo, F., Komine, O., Fujimori-Tonou, N., Katsuno, M., Jin, S., Watanabe, S., Sobue, G., Dezawa, M., Wyss-Coray, T., Yamanaka, K., Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 11 (2015), 592–604.
21. Eve, D.J., Ehrhart, J., Zesiewicz, T., Jahan, I., Kuzmin-Nichols, N., Sanberg, C.D., Gooch, C., Sanberg, P.R., Garbuzova-Davis, S., Plasma derived from human umbilical cord blood modulates mitogen-induced proliferation of mononuclear cells isolated from the peripheral blood of ALS patients. Cell Transplant. 25 (2016), 963–971.
22. Fang, F., Kwee, L.C., Allen, K.D., et al. Association between blood lead and the risk of amyotrophic lateral sclerosis. Am. J. Epidemiol. 171 (2010), 1126–1133.
23. Feldman, E.L., Boulis, N.M., Hur, J., et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann. Neurol. 75 (2014), 363–373.
24. Ferraiuolo, L., Kirby, J., Grierson, A.J., et al. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7 (2011), 616–630.
25. Garbuzova-Davis, S., Haller, E., Saporta, S., Kolomey, I., Nicosia, S.V., Sanberg, P.R., Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 9 (2007), 126–137.
26. Garbuzova-Davis, S., Hernandez-Ontiveros, D.G., Rodrigues, M.C., Haller, E., Frisina-Deyo, A., Mirtyl, S., Sallot, S., Saporta, S., Borlongan, C.V., Sanberg, P.R., Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 21 (2012), 114–128.
27. Garbuzova-Davis, S., Rodrigues, M.C., Mirtyl, S., Turner, S., Mitha, S., Sodhi, J., Suthakaran, S., Eve, D.J., Sanberg, C.D., Kuzmin-Nichols, N., Sanberg, P.R., Multiple intravenous administrations of human umbilical cord blood cells benefit in a mouse model of ALS. PLoS One, 7, 2012, e31254.
28. Ghosh, Z., Huang, M., Hu, S., Wilson, K.D., Dey, D., Wu, J.C., Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Res. 71 (2011), 5030–5039.
29. Gincberg, G., Arien-Zakay, H., Lazarovici, P., Lelkes, P.I., Neural stem cells: therapeutic potential for neurodegenerative diseases. Br. Med. Bull. 104 (2012), 7–19.
30. Giordana, M.T., Grifoni, S., Votta, B., Magistrello, M., Vercellino, M., Pellerino, A., Navone, R., Valentini, C., Calvo, A., Chiò, A., Neuropathology of olfactory ensheathing cell transplantation into the brain of two amyotrophic lateral sclerosis (ALS) patients. Brain Pathol. 20 (2010), 730–737.
31. Gossrau, G., Thiele, J., Konang, R., et al. Bone morphogenetic protein-mediated modulation of lineage diversification during neural differentiation of embryonic stem cells. Stem Cells 25 (2007), 939–949.
32. Goutman, S.A., Chen, K.S., Feldman, E.L., Recent advances and the future of stem cell therapies in amyotrophic lateral sclerosis. Neurotherapeutics 12 (2015), 428–448.
33. Hall, E.D., Oostveen, J.A., Gurney, M.E., Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23 (1998), 249–256.
34. Harper, J.M., Krishnan, C., Darman, J.S., et al. Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 7123–7128.
35. Hefferan, M.P., Galik, J., Kakinohana, O., et al. Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation. PLoS One, 7, 2012, e42614.
36. Hwang, D.H., Lee, H.J., Park, I.H., et al. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther. 16 (2009), 1234–1244.
37. Imamura, K., Inoue, H., Research on neurodegeneratice diseases using induced pluripotent stem cells. Psychogeriatrics 12 (2012), 115–119.
38. Islamov, R.R., Rizvanov, A.A., Mukhamedyarov, M.A., Salafutdinov, I.I., Garanina, E.E., Fedotova, V.Y., Solovyeva, V.V., Mukhamedshina, Y.O., Safiullov, Z.Z., Izmailov, A.A., Guseva, D.S., Zefirov, A.L., Kiyasov, A.P., Palotas, A., Symptomatic improvement, increased life-span and sustained cell homing in amyotrophic lateral sclerosis after transplantation of human umbilical cord blood cells genetically modified with adeno-viral vectors expressing a neuro-protective factor and a neural cell adhesion molecule. Curr. Gene Ther. 15 (2015), 266–276.
39. Kamao, H., Mandai, M., Okamoto, S., Sakai, N., Suga, A., Sugita, S., Kiryu, J., Takahashi, M., Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep. 2 (2014), 205–218.
40. Karussis, D., Karageorgiou, C., Vaknin-Dembinsky, A., et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 67 (2010), 1187–1194.
41. Kim, S.U., Hwang, D.H., Kim, B.G., et al. Human neural stem cells over-expressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Mol. Ther., 16(Suppl 1), 2008, S32.
42. Kim, K.S., Lee, H.J., An, J., et al. Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS mouse model. Cell Transplant. 23 (2014), 1585–1597.
43. Knippenberg, S., Thau, N., Dengler, R., Brinker, T., Petri, S., Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS One, 7, 2012, e36857.
44. Knippenberg, S., Thau, N., Schwabe, K., et al. Intraspinal injection of human umbilical cord blood-derived cells in neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener. Dis. 9 (2012), 107–120.
45. Kwon, M.S., Noh, M.Y., Oh, K.W., Cho, K.A., Kang, B.Y., Kim, K.S., Kim, Y.S., Kim, S.H., The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients. J. Neurochem. 131 (2014), 206–218.
46. Lewis, C.M., Suzuki, M., Therapeutic applications of mesenchymal stem cells for amyotrophic materal sclerosis. Stem Cell Res. Ther., 5, 2014, 32.
47. Li, Y., Bao, J., Khatibi, N.H., Chen, L., Wang, H., Duan, Y., Huang, H., Zhou, C., Olfactory ensheathing cell transplantation into spinal cord prolongs the survival of mutant SOD1(G93A) ALS rats through neuroprotection and remyelination. Anat. Rec. (Hoboken) 294 (2011), 847–857.
48. Li, Y., Chen, L., Zhao, Y., Bao, J., Xiao, J., Liu, J., Jiang, X., Zhou, C., Wang, H., Huang, H., Intracranial transplant of olfactory ensheathing cells can protect both upper and lower motor neurons in amyotrophic lateral sclerosis. Cell Transplant. 22 (2013), S51–65.
49. Lopez-Gonzalez, R., Kunckles, P., Velasco, I., Transient recovery in a rat model of familial amyotrophic lateral sclerosis after transplantation of motor neurons derived from mouse embryonic stem cells. Cell Transplant. 18 (2009), 1171–1181.
50. Lunn, J.S., Sakowski, S.A., Feldman, E.L., Concise review: stem cell therapies for amyotrophic lateral sclerosis recent advances and prospects for the future. Stem Cells 32 (2014), 1099–1109.
51. Malaspina, A., Puentes, F., Amor, S., Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int. Immunol. 27 (2015), 117–129.
52. Mao, Z., Zhang, S., Hong Chen, H., Stem cell therapy for amyotrophic lateral sclerosis. Cell Regen (Lond.), 4, 2015, 11.
53. Marconi, S., Bonaconsa, M., Scambi, I., et al. Systemic treatment with adipose derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model. Neuroscience 248 (2013), 333–343.
54. Mathieu, P., Battista, D., Depino, A., et al. The more you have, the less you get: the functional role of inflammation on neuronal differentiation of endogenous and transplanted neural stem cells in the adult brain. J. Neurochem. 112 (2010), 1368–1385.
55. Mazzini, L., Fagioli, F., Boccaletti, R., et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4 (2003), 158–161.
56. Mazzini, L., Mareschi, K., Ferrero, I., et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol. Res. 28 (2006), 523–526.
57. Mazzini, L., Mareschi, K., Ferrero, I., et al. Stem cell treatment in amyotrophic lateral sclerosis. J. Neurol. Sci. 265 (2008), 78–83.
58. Mazzini, L., Ferrero, I., Luparello, V., et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp. Neurol. 223 (2010), 229–237.
59. Mazzini, L., Gelati, M., Profico, D.C., et al. Human neural stem cell transplantation in ASL: initial results from a phase I trial. J. Transl. Med. 27 (2015), 13–17.
60. Mazzini, L., Vescovi, A., Cantello, R., et al. Stem cells therapy for ALS. Expert Opin. Biol. Ther. 16:2 (2016), 187–199.
61. Miller, R.G., Mitchell, J.D., Moore, D.H., Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 14, 2012, CD001447.
62. Moloney, E.B., de Winter, F., Verhaagen, J., ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the diseases. Front. Neurosci., 8, 2014, 252.
63. Morita, E., Watanabe, Y., Ishimoto, M., Nakano, T., Kitayama, M., Yasui, K., Fukada, Y., Doi, K., Karunaratne, A., Murrell, W.G., Sutharsan, R., Mackay-Sim, A., Hata, Y., Nakashima, K., A novel cell transplantation protocol and its application to an ALS mouse model. Exp. Neurol. 213 (2008), 431–438.
64. Morren, J.A., Galvez-Jimenez, N., Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs 21 (2012), 297–320.
65. Naganska, E., Matyja, E., Amyotrophic lateral sclerosis − looking for pathogenesis and effective therapy. Folia Neuropathol. 49 (2011), 1–13.
66. Naujock, M., Stanslowsky, N., Reinhardt, P., Sterneckert, J., Haase, A., Martin, U., Kim, K.S., Dengler, R., Wegner, F., Petri, S., Molecular and functional analyses of motor neurons generated from human cord-blood-derived induced pluripotent stem cells. Stem Cells Dev. 23 (2014), 3011–3020.
67. Neri, M., Maderna, C., Cavazzin, C., et al. Efficient in vitro labeling of human neural precursor cells with superparamagnetic iron oxide particles: relevance for in vivo cell tracking. Stem Cells 26 (2008), 505–516.
68. Nistor, G.I., Totoiu, M.O., Haque, N., et al. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 49 (2005), 385–396.
69. Nizzardo, M., Simone, C., Rizzo, F., et al. Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model. Hum. Mol. Genet. 23 (2014), 342–354.
70. Oh, K.W., Moon, C., Kim, H.Y., et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl. Med. 4 (2015), 590–597.
71. Paczkowska, E., Kaczyńska, K., Pius-Sadowska, E., et al. Humoral activity of cord blood-derived stem/progenitor cells: implications for stem cell-based adjuvant therapy of neurodegenerative disorders. PLoS One, 8, 2013, e83833.
72. Pandya, R.S., Zhu, H., Li, W., Bowser, R., Friedlander, R.M., Wang, X., Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 70 (2013), 4729–4745.
73. Petkau, A., Sawatzky, A., Hillier, C.R., Hoogstraten, J., Lead content of neuromuscular tissue in amyotrophic lateral sclerosis: case report and other considerations. Br. J. Ind. Med. 31 (1974), 275–287.
74. Philips, T., Robberecht, W., Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 10 (2011), 253–263.
75. Piepers, S., van den Berg, L.H., No benefits from experimental treatment with olfactory ensheathing cells in patients with ALS. Amyotroph. Lateral Scler. 11 (2010), 328–330.
76. Pluchino, S., Gritti, A., Blezer, E., Amadio, S., Brambilla, E., Borsellino, G., Cossetti, C., Del Carro, U., Comi, G., Hart, B., Vescovi, A., Martino, G., Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann. Neurol. 66 (2009), 343–354.
77. Popescu, I.R., Nicaise, C., Liu, S., et al. Neural progenitors derived from human induced pluripotent stem cells survive and differentiate upon transplantation into a rat model of amyotrophic lateral sclerosis. Stem Cells Transl. Med. 2 (2013), 167–174.
78. Prockop, D.J., Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276 (1997), 71–74.
79. Qureshi, I.A., Mehler, M.F., Epigenetic mechanisms governing the process of neurodegeneration. Mol. Aspects Med. 34 (2013), 875–882.
80. Reekmans, K., Praet, J., Daans, J., et al. Current challenges for the advancement of neural stem cell biology and transplantation research. Stem Cell Rev. 8 (2012), 262–278.
81. Riley, J., Glass, J., Feldman, E.L., et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery 74 (2014), 77–87.
82. Rizvanov, A.A., Guseva, D.S., Salafutdinov, I.I., et al. Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice. Exp. Biol. Med. (Maywood) 236 (2011), 91–98.
83. Robelin, L., Gonzalez De Aguilar, J.L., Blood biomarkers for amyotrophic lateral sclerosis: myth or reality?. BioMed. Res. Int., 2014, 2014, 525097.
84. Rodrigues, M.C., Voltarelli, J.C., Sanberg, P.R., Borlongan, C.V., Garbuzova-Davis, S., Immunological aspects in amyotrophic lateral sclerosis. Transl. Stroke Res. 3 (2012), 331–340.
85. Roy, N.S., Cleren, C., Singh, S.K., et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12 (2006), 1259–1268.
86. Sareen, D., Gowing, G., Sahabian, A., et al. Human induced pluripotent stem cells are a novel source of neural progenitor cells (iNPCs) that migrate and integrate in the rodent spinal cord. J. Comp. Neurol. 522 (2014), 2707–2728.
87. Souayah, N., Coakley, K.M., Chen, R., Ende, N., McArdle, J.J., Defective neuromuscular transmission in the SOD1 G93A transgenic mouse improves after administration of human umbilical cord blood cells. Stem Cell Rev. 8 (2012), 224–228.
88. Srivastava, A.K., Clinical relevance of stem cell therapies in amyotrophic lateral sclerosis. Neurol. India 62 (2014), 239–248.
89. Suzuki, M., McHugh, J., Tork, C., et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther. 16 (2008), 2002–2010.
90. Teng, Y.D., Benn, S.C., Kalkanis, S.N., et al. Multimodel actions of neural stem cells in a mouse model of ALS: A meta-analysis. Sci. Transl. Med., 4, 2012, 165ra164.
91. Tsuchiya, T., Park, K.C., Toyonaga, S., et al. Characterization of microglia induced from mouse embryonic stem cells and their migration into the brain parenchyma. J. Neuroimmunol. 160 (2005), 210–218.
92. Uccelli, A., Milanese, M., Principato, M.C., Morando, S., Bonifacino, T., Vergani, L., Giunti, D., Voci, A., Carminati, E., Giribaldi, F., Caponnetto, C., Bonanno, G., Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol. Med. 18 (2012), 794–804.
93. Vercelli, A., Mereuta, O.M., Garbossa, D., et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 31 (2008), 395–405.
94. Vinceti, M., Fiore, M., Signorelli, C., et al. Environmental risk factors for amyotrophic lateral sclerosis: methodological issues in epidemiologic studies. Ann. Ig. 5 (2012), 407–415.
95. Wang, Y., Chen, X., Cao, W., Shi, Y., Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15 (2014), 1009–1016.
96. Wichterle, H., Lieberam, I., Porter, J.A., Jessell, T.M., Directed differentiation of embryonic stem cells into motor neurons. Cell 110 (2002), 385–397.
97. Wijesekera, L.C., Leigh, P.N., Amyotrophic lateral sclerosis. Orphanet J. Rare Dis., 3(4), 2009, 3.
98. Willenbrock, S., Knippenberg, S., Meier, M., Hass, R., Wefstaedt, P., Nolte, I., Murua Escobar, H., Petri, S., In vivo MRI of intraspinally injected SPIO-labelled human CD34+ cells in a transgenic mouse model of ALS. In Vivo 26 (2012), 31–38.
99. Winkler, E.A., Sengillo, J.D., Sagare, A.P., Zhao, Z., Ma, Q., Zuniga, E., Wang, Y., Zhong, Z., Sullivan, J.S., Griffin, J.H., Cleveland, D.W., Zlokovic, B.V., Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E1035–42.
100. Xu, L., Ryugo, D.K., Pongstaporn, T., et al. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J. Comp. Neurol. 514 (2009), 297–309.
101. Xu, L., Shen, P., Hazel, T., et al. Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neurons disease in SOD1 transgenic rats. Neurosci. Lett. 494 (2011), 222–226.
102. Yan, J., Xu, L., Welsh, A.M., et al. Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med., 4, 2007, e39.
103. Yao, X.L., Ye, C.H., Liu, Q., et al. Motoneuron differentiation of induced pluripotent stem cells from SOD1G93A mice. PLoS One, 8, 2013, e64720.
104. Yu, J., Vodyanik, M.A., Smuga-Otto, K., et al. Induced pluripotent stem cell lines derived from human somatic cell. Science 318 (2007), 1917–1920.
105. Yu, Y., Su, F.C., Callaghan, B.C., et al. Environmental risk factors and amyotrophic lateral sclerosis (ALS): a case-control study of ALS in Michigan. PLoS One, 9, 2014, e101186.
106. Yunusova, Y., Graham, N.L., Shellikeri, S., et al. Profiling speech and pausing in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). PLoS One, 20, 2016, e0147573.
107. Zhao, C.P., Zhang, C., Zhou, S.N., Xie, Y.M., Wang, Y.H., Huang, H., Shang, Y.C., Li, W.Y., Zhou, C., Yu, M.J., Feng, S.W., Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy 9 (2007), 414–426.